Evidence map›Paper›PMID 34771629›Full record

ArticleCancers2021

The Role of Skin Tests in the Prevention and Diagnosis of Hypersensitivity Reactions to Platinum Agents in Gynecological Cancer: A Single-Center Italian Retrospective Study.

Ilaria Puxeddu, Fiorella Petrelli, Maria Elena Guerrieri, Stefania Cosio, Isabella Del Corso, Valeria Rocchi, Maria Laura Manca, Paola Migliorini, Angiolo Gadducci

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ilaria PuxedduImmunology and Allergology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56127 Pisa, Italy.
Fiorella PetrelliImmunology and Allergology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56127 Pisa, Italy.
Maria Elena GuerrieriDivision of Gynecology and Obstetrics, Department of Clinical and Experimental Medicine, University of Pisa, 56127 Pisa, Italy.
Stefania CosioDivision of Gynecology and Obstetrics, Department of Clinical and Experimental Medicine, University of Pisa, 56127 Pisa, Italy.
Isabella Del CorsoImmunology and Allergology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56127 Pisa, Italy.
Valeria RocchiImmunology and Allergology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56127 Pisa, Italy.
Maria Laura MancaInternal Medicine Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56127 Pisa, Italy.ORCID 0000-0002-9274-2313
Paola MiglioriniImmunology and Allergology Unit, Department of Clinical and Experimental Medicine, University of Pisa, 56127 Pisa, Italy.
Angiolo GadducciDivision of Gynecology and Obstetrics, Department of Clinical and Experimental Medicine, University of Pisa, 56127 Pisa, Italy.
University of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHypersensitivity reactions (HSR)s to platinum agents are increasing in frequency, due to their extensive use and repeated exposures in patients with increased life expectancy. The aims of our study are to analyze the frequency of both type I and type IV HSRs in patients with gynecological cancer treated with (CBDCA) carboplatin and/or (CDDP) cisplatin, to evaluate the role of skin tests in the diagnosis and prevention of HSRs.

methodsFrom 2011 to 2018, we evaluated 124 consecutive female patients previously treated with CBDCA and/or CDDP for gynecological cancer. All patients, including those with and without HSR to previous platinum-based therapy, underwent

resultsAmong the 124 patients evaluated, 58 (47%) experienced HSRs to at least one platinum agent: 35% were to CBDCA, 5% to CDDP, 7% to both. Fifty-six of the 58 HSRs were classified as immediate and two delayed. Skin tests confirmed an IgE-dependent mechanism in 67% of patients with immediate-HSRs to CBDCA and identified a cross-reactivity between platinum agents in 18% of patients. Moreover, among those who had never developed an HSRs during platinum-based therapy,

conclusionsOn the basis of our findings, skin test for platinum agents is a simple and sensitive tool for the diagnosis and prevention of HSRs to CBDCA and/or CDDP and can be useful for detecting possible cross-reactivity among platinum agents.

Indexed as

carboplatincisplatingynecological cancerhypersensitivity reactions

Identifiers

PMID34771629
PMCPMC8582380
OpenAlexW3208969266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.